Cobra Biologics announced several product development projects with Novolytics, Recopharma, and Vaccibody.
Cobra Biologics and Novolytics announced that the companies have developed two Staphylococcus aureus-based phage products for Phase I clinical trials with a 100-fold increase in upstream process yields. An existing process was transferred to Cobra’s phage team, which further developed the process in order to increase yields for the two S. aureus-based phage products. The process provides a path to producing suitable GMP material for human clinical trials, according to a Cobra Biologics press release.
In May, Cobra and Recopharma, a biotechnology company developing ophthalmic products, announced that Cobra Biologics will use its maxXpress platform service to deliver a program of vector construction using the UCOE technology, transfectant pool generation, and supply, purification, and protein characterization for a human Fc-fusion protein.
Cobra also announced that it will manufacture Vaccibody’s lead DNA vaccine candidate against HPV-induced malignancies, using its platform process to deliver a program of host strain generation, GMP cell banking, plasmid DNA production, and clinical trials supply.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.